Electronic Supplementary Material (ESI) for Green Chemistry. This journal is © The Royal Society of Chemistry 2023

# **Supporting Information**

# [3+2] Cycloaddition of Azides with Arynes Formed via C-H Deprotonation of

# **Aryl Sulfonium Salts**

Xing-Wei Gu, <sup>†a</sup> Yan-Hua Zhao <sup>†a</sup> and Xiao-Feng Wu <sup>\*a,b</sup>

[a] Leibniz-Institut für Katalyse e.V., 18059 Rostock, Germany, E-mail: Xiao-Feng.Wu@catalysis.de

[b] Dalian National Laboratory for Clean Energy, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, 116023 Dalian, Liaoning, China, E-mail: xwu2020@dicp.ac.cn

+ There authors contributed equally.

# Contents

1. General Experimental	S2
2. General procedure for the synthesis of substrates	S2
2.1 General procedure for the synthesis of azides.	S2
2.2 General procedure for the synthesis of aryl sulfonium salts	S3
3. General Procedure for the [3+2] Cycloaddition.	S5
4. Characterization and procedure of the products	S5
5. Transformation of products.	S23
5.1 Gram reaction	S23
5.2 Prcedure for the synthesis of 4t.	S24
5.3 Prcedure for the synthesis of 5al.	S24
5.4 Prcedure for the synthesis of 6al.	S25
5.5 Prcedure for the synthesis of 7al	S26
5.6 Prcedure for the synthesis of 8al.	S27
6. Reference	S28
7. NMR spectra of products	S29

## 1. General Experimental.

**Reagents and solvents:** Unless otherwise noted, the chemicals were commercially available from Sigma-Aldrich, TCI, BLD or Alfa Aesar and were used without further purification. PhCF<sub>3</sub> bought from TCI, >98.0%(GC). The reaction does not require the glovebox.

**Purification:** The products were isolated from the reaction mixture by column chromatography on silica gel 60, 0.063-0.2 mm, 70-230 mesh (Merck). Gradient flash chromatography was conducted eluting with PE/EA, PE refers to pentane and EA refers to ethyl acetate, they were listed as volume/volume ratios.

**Data collection:** GC-yields were calculated using hexadecane as internal standard. GC analysis was performed on an Agilent HP-7890A instrument with FID detector and HP-5 capillary column (polydimethylsiloxane with 5% phenyl groups, 30 m, 0.32 mm i.d., 0.25  $\mu$ m film thickness) using argon as carrier gas. High resolution mass spectra (HRMS) were recorded on Agilent 6210. NMR spectra were recorded on Bruker Avance 300 and Bruker ARX 400 spectrometers. Chemical shifts (ppm) are given relative to solvent: references for CDCl<sub>3</sub> were 7.26 ppm (<sup>1</sup>H NMR) and 77.00 ppm (<sup>13</sup>C NMR). All measurements were carried out at room temperature unless otherwise stated.

# 2. General procedure for the synthesis of substrates.

2.1 General procedure for the synthesis of azides.<sup>[1]</sup>

$$R-Br + NaN_3 \xrightarrow{DMAc, 80 \circ C} R-N_3$$

A solution of bromide (1 equiv.) and NaN<sub>3</sub> (1.5 eq.) in DMF (0.2M) was heated at 80 °C overnight. The reaction mixture was cooled, diluted with EtOAc, washed with  $H_2O$  and brine, dried over Na<sub>2</sub>SO<sub>4</sub> and concentrated under vacuum, the crude product was purified by silica gel chromatography (pentane/EA) to afford the corresponding product.



### 1-(3-azidopropoxy)-4-(2-phenylpropan-2-yl)benzene (2k)

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.33 – 7.25 (m, 4H), 7.22 – 7.12 (m, 3H), 6.90 – 6.78 (m, 2H), 4.05 (t, *J* = 5.9 Hz, 2H), 3.54 (t, *J* = 6.7 Hz, 2H), 2.14 – 1.99 (m, 2H), 1.69 (s, 6H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ156.5, 150.8, 143.2, 127.9, 127.8, 126.7, 125.5, 113.8, 64.4, 48.3, 42.3, 30.9, 28.8.

2.2 General procedure for the synthesis of aryl sulfonium salts.<sup>[2]</sup>



Aryl thianthrenium triflates were prepared by known literature procedure. Thianthrene S-oxide (1 equiv.), simple arene (1 equiv.) and acetonitrile (0.25M) were added to an appropriately sized vial, equipped with a magnetic stir bar. Trifluoromethanesulfonic acid (1.5 equiv.) was added in one portion, followed by one portion of trifluoroacetic anhydride (3 equiv.). The vial was capped and stirred vigorously at room temperature for 12 hours. Methanol was then added until the reactions dark color dissipated. The mixture was then concentrated under reduced pressure to afford an oily residue. This residue was then triturated with diethyl ether until precipitation ceased. The precipitate was isolated by vacuum filtration and washed by slurry filtration with diethyl ether ( $3 \times 10$  mL). After drying under air for 15 minutes the aryl thianthrenium triflate was obtained in pure form.



#### Aryl Sulfonium Salts 1an

<sup>1</sup>H NMR (300 MHz, DMSO) δ 8.30 (dt, *J* = 8.1, 1.3 Hz, 2H), 8.14 – 8.04 (m, 2H), 7.96 – 7.62 (m, 4H), 7.37 (d, *J* = 12.3 Hz, 1H), 6.47 (d, *J* = 6.9 Hz, 1H), 3.85 (s, 3H), 3.57 (s, 3H).

<sup>13</sup>C NMR (75 MHz, DMSO) δ 156.0 (d, *J* = 245.3 Hz), 155.8 (d, *J* = 10.3 Hz), 146.3, 135.3, 134.9, 134.3, 130.6, 130.3, 119.6, 112.0, 103.3 (d, *J* = 25.8 Hz), 99.7 (d, *J* = 15.4 Hz), 57.4, 56.8.

<sup>19</sup>F NMR (282 MHz, DMSO) δ -77.74.

HRMS (ESI-TOF): m/z calcd. for  $C_{20}H_{16}FO_2S_2^+$  [M]<sup>+</sup> 371.0571, found 371.0575.



#### Aryl Sulfonium Salts 1ao

<sup>1</sup>H NMR (300 MHz, DMSO) δ 8.45 – 8.36 (m, 2H), 8.12 – 8.03 (m, 2H), 7.95 – 7.73 (m, 4H), 7.35 (dd, *J* = 6.0, 0.8 Hz, 1H), 6.43 (d, *J* = 8.5 Hz, 1H), 3.91 (s, 3H), 2.26 (d, *J* = 1.5 Hz, 3H).

<sup>13</sup>C NMR (75 MHz, DMSO)  $\delta$  154.7 (d, J = 239.9 Hz), 153.9 (d, J = 1.6 Hz), 136.5, 136.0, 135.0, 133.7 (d, J = 18.8 Hz), 130.9, 129.9, 118.0, 117.4 (d, J = 4.3 Hz), 115.5 (d, J = 28.7 Hz), 108.2 (d, J = 8.3 Hz), 57.9, 15.1 (d, J = 2.7 Hz).

<sup>19</sup>F NMR (282 MHz, DMSO) δ -77.74.

HRMS (ESI-TOF): m/z calcd. for  $C_{20}H_{16}FOS_2^+$  [M]<sup>+</sup> 355.0622, found 355.0621.



### Aryl Sulfonium Salts 1ap

<sup>1</sup>H NMR (300 MHz, DMSO) δ 8.17 – 8.05 (m, 4H), 7.95 – 7.83 (m, 3H), 7.69 (ddd, *J*=8.1, 7.4, 1.3 Hz, 2H), 7.52 – 7.44 (m, 3H), 7.41 – 7.33 (m, 3H), 6.63 (d, *J*=2.3 Hz, 1H), 5.34 (s, 2H).

<sup>13</sup>C NMR (75 MHz, DMSO) δ 156.2, 138.5, 136.7, 136.3, 135.1, 135.0, 131.1, 130.9, 129.9, 129.4, 129.2, 117.7, 112.7, 112.0, 72.2.

HRMS (ESI-TOF): m/z calcd. for  $C_{25}H_{18}BrOS_2^+$  [M]<sup>+</sup> 476.9977, found 476.9970.



### Aryl Sulfonium Salts 1aq

<sup>1</sup>H NMR (300 MHz, DMSO) δ 8.50 – 8.38 (m, 2H), 8.16 – 8.07 (m, 2H), 7.97 – 7.75 (m, 4H), 7.54 (s, 1H), 6.47 (d, *J* = 0.4 Hz, 1H), 3.85 (s, 3H), 3.52 (s, 3H).

<sup>13</sup>C NMR (75 MHz, DMSO) δ 154.3, 149.0, 136.2, 135.9, 135.1, 130.9, 130.1, 119.3, 118.6, 116.5, 113.8, 113.8, 57.3, 56.4.

HRMS (ESI-TOF): m/z calcd. for  $C_{20}H_{16}BrO_2S_2^+$  [M]<sup>+</sup> 430.9770, found 430.9763.



### Aryl Sulfonium Salts 1ar

<sup>1</sup>H NMR (300 MHz, DMSO) δ 8.48 (dd, *J* = 8.0, 1.4 Hz, 2H), 8.11 (dd, *J* = 7.9, 1.4 Hz, 2H), 7.91 (td, *J* = 7.7, 1.5 Hz, 2H), 7.80 (td, *J* = 7.7, 1.4 Hz, 2H), 7.65 (s, 1H), 6.59 (s, 1H), 6.20 (s, 2H).

<sup>13</sup>C NMR (75 MHz, DMSO) δ 153.5, 148.9, 136.6, 136.0, 135.1, 131.2, 130.0, 119.1, 117.9, 115.6, 115.5, 110.6, 104.6.

HRMS (ESI-TOF): m/z calcd. for  $C_{19}H_{12}BrO_2S_2^+$  [M]<sup>+</sup> 414.9457, found 414.9448.

3. General Procedure for the [3+2] Cycloaddition.



A 5 mL snap vial equipped with a magnetic stir bar was charged with aryl sulfonium salts (0.3 mmol, 1.5 equiv.), NaOtBu (0.4 mmol, 2.0 equiv.). PhCF<sub>3</sub> (2 mL) and substrate azides (0.2 mmol, 1.0 equiv.) were added via syringe. The reaction mixture was stirred (500 rpm) at 80 °C for 6 h. After reaction, cooling to room temperature. The crude product was purified by silica gel chromatography (pentane/EA) to afford the corresponding product.

# 4. Characterization and procedure of the products



### 1-benzyl-1*H*-benzo[*d*] [1,2,3] triazole (3a)<sup>[3]</sup>

Chromatography Pentane/EA = 10:1 (v/v), 34.6 mg (83%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.98 (dt, J = 7.7, 1.3 Hz, 1H), 7.38 – 7.13 (m, 8H), 5.76 (s, 2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 146.2, 134.7, 132.7, 128.9, 128.4, 127.5, 127.4, 123.9, 120.0, 109.7, 52.2.



### 1-(4-chlorobenzyl)-1*H*-benzo[d] [1,2,3] triazole (3b)<sup>[3]</sup>

Chromatography Pentane/EA = 10:1 (v/v), 28.8 mg (59%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.05 – 7.94 (m, 1H), 7.38 – 7.18 (m, 5H), 7.15 – 7.09 (m, 2H), 5.72 (s, 2H). <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 146.2, 134.4, 133.2, 132.6, 129.2, 128.9, 127.6, 124.0, 120.1, 109.4, 51.4.



#### 1-(4-bromobenzyl)-1*H*-benzo[d] [1,2,3] triazole (3c)<sup>[4]</sup>

Chromatography Pentane/EA = 10:1 (v/v), 32.9 mg (57%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.12 – 8.02 (m, 1H), 7.52 – 7.26 (m, 5H), 7.19 – 7.07 (m, 2H), 5.79 (s, 2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 146.2, 133.7, 132.6, 132.1, 129.2, 127.6, 124.0, 122.5, 120.1, 109.4, 51.5.



#### 1-(2-bromobenzyl)-7-chloro-4-methoxy-1*H*-benzo[*d*] [1,2,3] triazole (3d)

Chromatography Pentane/EA = 10:1 (v/v), 64.8 mg (92%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.67 – 7.55 (m, 1H), 7.30 (d, J = 8.3 Hz, 1H), 7.21 – 7.06 (m, 2H), 6.64 (d, J = 8.3 Hz, 1H), 6.39 – 6.29 (m, 1H), 6.19 (s, 2H), 4.11 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 150.7, 139.2, 135.7, 132.8, 131.5, 129.2, 129.0, 127.7, 127.1, 121.3, 106.9, 104.4, 56.4, 52.6.

HRMS (ESI-TOF): m/z calcd. for  $C_{14}H_{11}BrClN_3ONa^+$  [M+Na<sup>+</sup>] 373.9666, found 373.9670.



### 7-chloro-1-(2-iodobenzyl)-4-methoxy-1*H*-benzo[*d*] [1,2,3] triazole (3e)

Chromatography Pentane/EA = 10:1 (v/v), 71.8 mg (90%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.88 (dd, J = 7.9, 1.3 Hz, 1H), 7.28 (d, J = 8.3 Hz, 1H), 7.14 (td, J = 7.6, 1.3 Hz, 1H), 7.02 – 6.91 (m, 1H), 6.63 (d, J = 8.3 Hz, 1H), 6.29 – 6.19 (m, 1H), 6.09 (s, 2H), 4.10 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 150.7, 139.5, 139.3, 138.7, 131.5, 129.4, 129.1, 128.6, 126.6, 107.0, 104.5, 96.1, 57.4, 56.5.

HRMS (ESI-TOF): m/z calcd. for  $C_{14}H_{11}CIIN_3ONa^+$  [M+Na<sup>+</sup>] 421.9527, found 421.9533.



### 1-hexyl-1*H*-benzo[*d*] [1,2,3] triazole (3f)<sup>[5]</sup>

Chromatography Pentane/EA = 20:1 (v/v), 30.5 mg (75%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.05 (dt, J = 8.3, 1.0 Hz, 1H), 7.56 – 7.43 (m, 2H), 7.41 – 7.32 (m, 1H), 4.63 (t, J = 7.2 Hz, 2H), 2.08 – 1.92 (m, 2H), 1.43 – 1.18 (m, 6H), 1.00 – 0.79 (m, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 145.9, 132.9, 127.1, 123.7, 120.0, 109.3, 48.2, 31.2, 29.6, 26.4, 22.4, 13.9.



1-octyl-1*H*-benzo[*d*] [1,2,3] triazole (3g)<sup>[6]</sup>

Chromatography Pentane/EA = 20:1 (v/v), 36.0 mg (78%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.06 (dt, J = 8.3, 1.0 Hz, 1H), 7.56 – 7.43 (m, 2H), 7.36 (ddd, J = 8.1, 6.5, 1.4 Hz, 1H), 4.63 (t, J = 7.2 Hz, 2H), 2.08 – 1.92 (m, 2H), 1.42 – 1.14 (m, 10H), 0.93 – 0.79 (m, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 145.9, 132.9, 127.1, 123.7, 120.0, 109.3, 48.2, 31.7, 29.7, 29.0, 29.0, 26.7, 22.5, 14.0.



### 1-(3-phenylpropyl)-1*H*-benzo[*d*] [1,2,3] triazole (3h) [7]

Chromatography Pentane/EA = 20:1 (v/v), 35.1 mg (74%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.99 (dt, *J* = 8.3, 1.0 Hz, 1H), 7.45 – 7.31 (m, 2H), 7.34 – 7.23 (m, 1H), 7.27 – 7.15 (m, 2H), 7.19 – 7.04 (m, 3H), 4.55 (t, *J* = 7.0 Hz, 2H), 2.67 – 2.54 (m, 2H), 2.37 – 2.21 (m, 2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ145.9, 140.2, 132.9, 128.5, 128.4, 127.2, 126.3, 123.8, 120.0, 109.2, 47.3, 32.6, 30.9.



7-chloro-4-methoxy-1-(2-phenylpropyl)-1*H*-benzo[*d*][1,2,3]triazole (3i)

Chromatography Pentane/EA = 10:1 (v/v), 47.4 mg (79%), 13:1 rr.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.26 – 6.89 (m, 6H), 6.45 (d, *J* = 8.3 Hz, 1H), 5.78 – 5.61 (m, 1H), 3.97 (s, 3H), 3.45 (dd, *J* = 13.6, 7.5 Hz, 1H), 3.16 (dd, *J* = 13.6, 7.3 Hz, 1H), 1.67 (d, *J* = 6.7 Hz, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 150.5, 138.9, 137.3, 131.0, 129.1, 128.6, 128.3, 126.6, 106.7, 103.6, 57.1, 56.3, 43.5, 21.0.

HRMS (ESI-TOF): m/z calcd. for  $C_{16}H_{16}CIN_3ONa^+$  [M+Na<sup>+</sup>] 324.0874, found 324.0879.



### 1-(4-methoxybutyl)-1*H*-benzo[*d*] [1,2,3] triazole (3j)

Chromatography Pentane/EA = 5:1 (v/v), 34.0 mg (83%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.04 (dt, *J* = 8.3, 1.0 Hz, 1H), 7.58 – 7.41 (m, 2H), 7.35 (ddd, *J* = 8.1, 6.7, 1.3 Hz, 1H), 4.66 (t, *J* = 7.1 Hz, 2H), 3.38 (t, *J* = 6.1 Hz, 2H), 3.29 (s, 3H), 2.09 (tt, *J* = 7.4, 6.6 Hz, 2H), 1.70 – 1.53 (m, 2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 145.8, 132.9, 127.2, 123.8, 119.9, 109.3, 71.7, 58.5, 48.0, 26.7, 26.6.

HRMS (ESI-TOF): m/z calcd. for  $C_{11}H_{15}N_3ONa^+$  [M+Na<sup>+</sup>] 228.1107, found 228.1110.



#### 1-(3-(4-(2-phenylpropan-2-yl) phenoxy) propyl)-1*H*-benzo[d] [1,2,3] triazole (3k)

Chromatography Pentane/EA = 8:1 (v/v), 50.4 mg (65%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.97 (dt, *J* = 8.2, 1.1 Hz, 1H), 7.50–7.40 (m, 1H), 7.37–7.30 (m, 1H), 7.29–7.23 (m, 1H), 7.21–7.00 (m, 7H), 6.75–6.62 (m, 2H), 4.76 (t, *J* = 6.8 Hz, 2H), 3.85 (t, *J* = 5.7 Hz, 2H), 2.46–2.27 (m, 2H), 1.57 (s, 6H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ 156.2, 150.8, 145.7, 143.3, 133.2, 127.9, 127.8, 127.3, 126.6, 125.5, 123.9, 119.9, 113.8, 109.3, 64.0, 44.7, 42.2, 30.8, 29.6.



#### 5-(1*H*-benzo[*d*] [1,2,3] triazol-1-yl) pentanenitrile (31)

Chromatography Pentane/EA = 3:1 (v/v), 21.4 mg (53%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.06 (dt, J = 8.3, 1.0 Hz, 1H), 7.58 – 7.42 (m, 2H), 7.42 – 7.33 (m, 1H), 4.70 (t, J = 6.7 Hz, 2H), 2.40 (t, J = 7.0 Hz, 2H), 2.27 – 2.11 (m, 2H), 1.77 – 1.61 (m, 2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 145.9, 132.7, 127.5, 124.0, 120.1, 118.9, 109.0, 46.9, 28.3, 22.4, 16.6.

HRMS (ESI-TOF): m/z calcd. for  $C_{11}H_{12}N_4Na^+$  [M+Na<sup>+</sup>] 223.0954, found 223.0954.



#### 7-chloro-1-(hex-5-en-1-yl)-4-methoxy-1*H*-benzo[*d*][1,2,3]triazole (3m)

Chromatography Pentane/EA = 15:1 (v/v), 46.3 mg (87%), 17:1 rr.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.29 (d, *J* = 8.3 Hz, 1H), 6.58 (d, *J* = 8.3 Hz, 1H), 5.84 – 5.65 (m, 1H), 5.05 – 4.74 (m, 4H), 4.06 (s, 3H), 2.17 – 1.91 (m, 4H), 1.46 (tt, *J* = 9.9, 6.5 Hz, 2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ150.7, 139.2, 137.9, 131.2, 128.5, 115.0, 106.8, 103.8, 56.3, 49.3, 33.0, 30.7, 25.5.

HRMS (ESI-TOF): m/z calcd. for  $C_{13}H_{16}ClN_3ONa^+$  [M+Na<sup>+</sup>] 288.0874, found 288.0879.



### 1-(2-(1,3-dioxolan-2-yl)ethyl)-1*H*-benzo[d] [1,2,3] triazole (3n)

Chromatography Pentane/EA = 5:1 (v/v), 32.9 mg (75%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.06 – 7.97 (m, 1H), 7.59 – 7.51 (m, 1H), 7.50 – 7.42 (m, 1H), 7.38 – 7.30 (m, 1H), 4.90 (t, J = 4.3 Hz, 1H), 4.81 – 4.73 (m, 2H), 4.04 – 3.75 (m, 4H), 2.42 – 2.33 (m, 2H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 145.8, 132.9, 127.2, 123.8, 120.0, 109.3, 101.5, 65.0, 43.0, 33.5.

HRMS (ESI-TOF): m/z calcd. for  $C_{11}H_{13}N_3O_2Na^+$  [M+Na<sup>+</sup>] 242.0900, found 242.0905.



### 1-(2-(2,3-dihydrobenzofuran-5-yl) ethyl)-1*H*-benzo[*d*] [1,2,3] triazole (30)

Chromatography Pentane/EA = 5:1 (v/v), 41.9 mg (79%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.00 – 7.89 (m, 1H), 7.49 – 7.07 (m, 3H), 6.86 – 6.70 (m, 2H), 6.64 – 6.53 (m, 1H), 4.76 – 4.65 (m, 2H), 4.42 (t, *J* = 8.7 Hz, 2H), 3.19 – 3.07 (m, 2H), 2.98 (t, *J* = 8.7 Hz, 2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ 159.1, 145.7, 133.0, 129.1, 128.1, 127.4, 127.0, 125.2, 123.7, 119.8, 109.3, 109.2, 71.1, 50.0, 35.7, 29.5.

HRMS (ESI-TOF): m/z calcd. for C<sub>16</sub>H<sub>15</sub>N<sub>3</sub>ONa<sup>+</sup> [M+Na<sup>+</sup>] 288.1107, found 288.1111.



#### 1-(2-(thiophen-2-yl)ethyl)-1*H*-benzo[*d*][1,2,3]triazole (3p)

Chromatography Pentane/EA = 8:1 (v/v), 33.7 mg (74%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.96 (dt, J = 8.2, 1.1 Hz, 1H), 7.39 – 7.10 (m, 4H), 6.83 – 6.73 (m, 2H), 4.77 (t, J = 7.2 Hz, 2H), 3.27 (t, J = 7.2 Hz, 2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ145.7, 137.4, 133.0, 127.7, 127.2, 126.2, 123.7, 122.2, 119.8, 109.0, 48.9, 30.6.

HRMS (ESI-TOF): m/z calcd. for  $C_{12}H_{11}N_3SNa^+$  [M+Na<sup>+</sup>] 252.0566, found 252.0572.



#### 1-cyclohexyl-1*H*-benzo[*d*] [1,2,3] triazole (3q) [8]

Chromatography Pentane/EA = 20:1 (v/v), 27.3 mg (68%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.05 (dt, J = 8.3, 1.0 Hz, 1H), 7.57 (dt, J = 8.4, 1.0 Hz, 1H), 7.49 – 7.41 (m, 1H), 7.34 (ddd, J = 8.1, 6.9, 1.1 Hz, 1H), 4.76 – 4.55 (m, 1H), 2.27 – 2.06 (m, 4H), 2.05 – 1.92 (m, 2H), 1.88 – 1.73 (m, 1H), 1.62 – 1.21 (m, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 146.0, 132.2, 126.7, 123.7, 120.0, 109.7, 59.0, 32.5, 25.5, 25.2.



### tert-butyl 4-(1H-benzo[d] [1,2,3] triazol-1-yl) piperidine-1-carboxylate (3r)

Chromatography Pentane/EA = 8:1 (v/v), 43.2 mg (71%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.04 (dt, J = 8.3, 1.0 Hz, 1H), 7.55 (dt, J = 8.3, 1.0 Hz, 1H), 7.50 – 7.41 (m, 1H), 7.39 – 7.30 (m, 1H), 4.88 – 4.76 (m, 1H), 4.28 (dd, J = 24.7, 9.5 Hz, 2H), 3.01 (t, J = 12.7 Hz, 2H), 2.42 – 2.22 (m, 2H), 2.20 – 2.09 (m, 2H), 1.48 (s, 9H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 154.5, 146.0, 132.1, 129.4, 123.9, 120.1, 109.4, 80.0, 56.9, 31.4, 28.3.

HRMS (ESI-TOF): m/z calcd. for  $C_{16}H_{22}N_4O_2Na^+$  [M+Na<sup>+</sup>] 325.1635, found 325.1633.



### 1-(tetrahydro-2*H*-pyran-4-yl)-1*H*-benzo[*d*] [1,2,3] triazole (3s)

Chromatography Pentane/EA = 5:1 (v/v), 30.1 mg (74%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.06 (dt, J = 8.3, 1.0 Hz, 1H), 7.59 (dt, J = 8.3, 1.0 Hz, 1H), 7.51 – 7.43 (m, 1H), 7.41 – 7.32 (m, 1H), 4.92 (tt, J = 11.6, 4.3 Hz, 1H), 4.24 – 4.14 (m, 2H), 3.70 – 3.59 (m, 2H), 2.58 – 2.43 (m, 2H), 2.18 – 2.07 (m, 2H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>) δ 146.1, 132.0, 127.1, 123.9, 120.2, 109.5, 66.9, 56.0, 32.2.

HRMS (ESI-TOF): m/z calcd. for  $C_{11}H_{13}N_3ONa^+$  [M+Na<sup>+</sup>] 204.1137, found 204.1138.

$$\bigvee_{i=1}^{N=N} N_{i}$$

#### 1-(5-azidopentyl)-1*H*-benzo[*d*] [1,2,3] triazole (3t)

Chromatography Pentane/EA = 5:1 (v/v), 27.7 mg (60%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.07 (dt, *J* = 8.3, 1.0 Hz, 1H), 7.57 – 7.44 (m, 2H), 7.37 (ddd, *J* = 8.4, 6.0, 1.9 Hz, 1H), 4.65 (t, *J* = 7.0 Hz, 2H), 3.25 (t, *J* = 6.8 Hz, 2H), 2.14 – 1.98 (m, 2H), 1.71 – 1.56 (m, 2H), 1.50 – 1.35 (m, 2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 145.9, 132.9, 127.3, 123.9, 120.1, 109.1, 51.1, 47.9, 29.2, 28.3, 23.9.

HRMS (ESI-TOF): m/z calcd. for  $C_{11}H_{14}N_6Na^+$  [M+Na<sup>+</sup>] 253.1172, found 253.1175.



#### 5-(1*H*-benzo[d] [1,2,3] triazol-1-yl) pentyl 5-(2,5-dimethylphenoxy)-2,2-dimethylpentanoate (3u)

Chromatography Pentane/EA = 5:1 (v/v), 51.0 mg (58%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.08 (dt, *J* = 8.3, 1.1 Hz, 1H), 7.56 – 7.45 (m, 2H), 7.43 – 7.34 (m, 1H), 7.01 (d, *J* = 7.4 Hz, 1H), 6.71 – 6.60 (m, 2H), 4.65 (t, *J* = 7.0 Hz, 2H), 4.06 (t, *J* = 6.5 Hz, 2H), 3.99 – 3.85 (m, 2H), 2.32 (s, 3H), 2.19 (s, 3H), 2.15 – 1.99 (m, 2H), 1.82 – 1.62 (m, 6H), 1.51 – 1.33 (m, 2H), 1.19 (s, 6H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ 177.7, 156.8, 145.8, 136.4, 132.8, 130.2, 127.2, 123.8, 123.4, 119.9, 111.9, 109.1, 67.8, 63.7, 47.8, 42.0, 36.9, 29.1, 28.0, 25.1, 25.0, 23.1, 21.3, 15.7.

HRMS (ESI-TOF): m/z calcd. for  $C_{26}H_{35}N_3O_3Na^+$  [M+Na<sup>+</sup>] 460.2570, found 460.2564.



### 1-phenyl-1*H*-benzo[*d*][1,2,3]triazole (3v) <sup>[9]</sup>

Chromatography Pentane/EA = 10:1 (v/v), 27.4 mg (70%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.14 (dt, J = 8.3, 1.0 Hz, 1H), 7.83 - 7.69 (m, 3H), 7.64 - 7.37 (m, 5H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 146.4, 136.9, 132.2, 129.8, 128.6, 128.2, 124.3, 122.8, 120.2, 110.3.



### 1-(*p*-tolyl)-1*H*-benzo[*d*][1,2,3]triazole (3w) [10]

Chromatography Pentane/EA = 10:1 (v/v), 29.0 mg (69%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.10 (dt, J = 8.2, 1.0 Hz, 1H), 7.65 (dt, J = 8.4, 1.0 Hz, 1H), 7.58 – 7.52 (m, 2H), 7.52 – 7.45 (m, 1H), 7.43 – 7.36 (m, 1H), 7.36 – 7.30 (m, 2H), 2.39 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 144.8, 139.5, 134.0, 132.5, 130.5, 128.6, 125.3, 123.0, 119.5, 110.7, 21.2.



### 1-(*m*-tolyl)-1*H*-benzo[*d*][1,2,3]triazole (3x)<sup>[11]</sup>

Chromatography Pentane/EA = 10:1 (v/v), 27.1 mg (65%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.16 (dt, J = 8.2, 1.0 Hz, 1H), 7.58 – 7.30 (m, 7H), 2.13 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 145.6, 135.3, 135.2, 133.9, 131.6, 130.0, 128.0, 127.0, 126.9, 124.1, 120.0, 110.1, 17.8.



### 1-(*o*-tolyl)-1*H*-benzo[*d*][1,2,3]triazole (3y)<sup>[11]</sup>

Chromatography Pentane/EA = 10:1 (v/v), 25.9 mg (62%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.14 (dt, J = 8.3, 1.0 Hz, 1H), 7.74 (dt, J = 8.3, 1.0 Hz, 1H), 7.63 – 7.59 (m, 1H), 7.59 – 7.39 (m, 4H), 7.35 – 7.28 (m, 1H), 2.49 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 146.4, 140.1, 136.8, 132.3, 129.5, 129.4, 128.1, 124.3, 123.5, 120.2, 119.8, 110.4, 21.4.



#### 1-(2,4-dimethylphenyl)-1*H*-benzo[*d*][1,2,3]triazole (3z)<sup>[12]</sup>

Chromatography Pentane/EA = 10:1 (v/v), 32.0 mg (72%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.08 (d, *J* = 8.3 Hz, 1H), 7.47 – 7.15 (m, 5H), 7.12 (s, 1H), 2.32 (s, 3H), 1.99 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ136.9, 134.9, 131.9, 131.3, 130.7, 127.9, 127.4, 124.0, 119.9, 110.2, 20.7, 17.2.



#### 1-(4-fluorophenyl)-1*H*-benzo[*d*][1,2,3]triazole (3aa)<sup>[11]</sup>

Chromatography Pentane/EA = 10:1 (v/v), 27.3 mg (64%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.14 (dt, J = 8.3, 1.0 Hz, 1H), 7.79 – 7.72 (m, 2H), 7.68 (dt, J = 8.4, 1.0 Hz, 1H), 7.60 – 7.51 (m, 1H), 7.48 – 7.39 (m, 1H), 7.36 – 7.27 (m, 2H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)δ 162.3 (d, J = 249.1 Hz), 146.4, 133.1 (d, J = 3.2 Hz), 132.3, 128.4, 124.8 (d, J = 8.6 Hz), 124.4, 120.3, 116.8 (d, J = 23.1 Hz), 110.0.

 $^{19}F$  NMR (376 MHz, CDCl<sub>3</sub>)  $\delta$  -111.91 – -112.06 (m, 1F).



### 1-(4-chlorophenyl)-1*H*-benzo[*d*][1,2,3]triazole (3ab)<sup>[11]</sup>

Chromatography Pentane/EA = 10:1 (v/v), 38.0 mg (83%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.13 (d, J = 8.4 Hz, 1H), 7.79 – 7.65 (m, 3H), 7.63 – 7.49 (m, 3H), 7.49 – 7.37 (m, 1H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 146.4, 135.4, 134.3, 132.0, 130.0, 128.5, 124.5, 123.8, 120.4, 110.0.



#### 1-(4-methoxyphenyl)-1*H*-benzo[*d*][1,2,3]triazole (3ac)<sup>[13]</sup>

Chromatography Pentane/EA = 5:1 (v/v), 31.5 mg (70%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.11 (dt, *J* = 8.3, 1.0 Hz, 1H), 7.70 – 7.59 (m, 3H), 7.54 – 7.47 (m, 1H), 7.45 – 7.37 (m, 1H), 7.15 – 7.04 (m, 2H), 3.89 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 159.8, 146.2, 132.6, 129.9, 128.0, 124.5, 124.2, 120.1, 114.9, 110.2, 55.6.





#### 1-(2-(trifluoromethyl)phenyl)-1*H*-benzo[*d*][1,2,3]triazole (3ad)

Chromatography Pentane/EA = 10:1 (v/v), 31.5 mg (60%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.14 (dt, *J* = 8.2, 1.0 Hz, 1H), 8.01 – 7.88 (m, 1H), 7.88 – 7.69 (m, 2H), 7.57 – 7.37 (m, 3H), 7.34 – 7.28 (m, 1H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 145.3, 134.9, 133.7 (q, *J* = 1.5 Hz), 133.1, 130.7, 129.8, 128.4, 128.2 (q, *J* = 31.4 Hz), 127.8 (q, *J* = 4.8 Hz), 124.3, 122.6 (q, *J* = 272.2 Hz), 120.0, 109.8.

<sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>) δ -59.90 (s, 3F).

HRMS (ESI-TOF): m/z calcd. for  $C_{13}H_8F_3N_3H^+$  [M+H<sup>+</sup>] 264.0749, found 264.0751.



### 4-(7-chloro-4-methoxy-1*H*-benzo[*d*][1,2,3]triazol-1-yl)benzonitrile (3ae)

Chromatography Pentane/EA = 3:1 (v/v), 41.2 mg (73%), 4.5:1 rr.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.91 – 7.78 (m, 2.79H), 7.76 – 7.70 (m, 1.88H), 7.42 (d, *J* = 8.4 Hz, 0.96H), 7.36 (d, *J* = 8.3 Hz, 0.23H), 6.85 (d, *J* = 8.3 Hz, 0.24H), 6.74 (d, *J* = 8.4 Hz, 0.99H), 4.13 (s, 3H), 3.88 (s, 0.67H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 150.9, 144.5, 139.4, 139.1, 132.6, 132.6, 131.3, 130.5, 127.9, 126.1, 124.9, 117.7, 113.58, 108.2, 106.8, 105.1, 56.7, 56.1.

HRMS (ESI-TOF): m/z calcd. for  $C_{14}H_9CIN_4OH^+$  [M+H<sup>+</sup>] 285.0543, found 285.0541.



### 1-(2-(phenylthio)phenyl)-1*H*-benzo[*d*][1,2,3]triazole (3af)

Chromatography Pentane/EA = 6:1 (v/v), 40.6 mg (67%).

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.16 – 8.09 (m, 1H), 7.54 – 7.45 (m, 2H), 7.44 – 7.38 (m, 4H), 7.37 – 7.32 (m, 1H), 7.23 (s, 5H).

<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>)δ145.5, 136.0, 134.9, 133.6, 132.9, 132.5, 131.5, 130.4, 129.3, 128.3, 128.0, 127.9, 127.4, 124.1, 120.0, 110.4.

HRMS (ESI-TOF): m/z calcd. for  $C_{18}H_{13}N_3SNa^+$  [M+Na<sup>+</sup>] 326.0722, found 326.0730.



### 4-(7-chloro-4-methoxy-1*H*-benzo[*d*][1,2,3]triazol-1-yl)-*N*,*N*-diethylaniline (3ag)

Chromatography Pentane/EA = 5:1 (v/v), 13.0 mg (20%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.32 (d, J = 8.3 Hz, 3H), 6.68 (dd, J = 26.0, 8.4 Hz, 3H), 4.12 (s, 3H), 3.43 (q, J = 7.1 Hz, 4H), 1.22 (t, J = 7.1 Hz, 6H).

 $^{13}C NMR (75 MHz, CDCl_3) \\ \delta 150.6, 148.6, 138.8, 135.3, 132.0, 129.0, 128.4, 110.6, 107.7, 104.0, 56.5, 44.5, 12.4.$ 

HRMS (ESI-TOF): m/z calcd. for  $C_{17}H_{19}CIN_4ONa^+$  [M+Na<sup>+</sup>] 353.1139, found 353.1139.



#### 1-(naphthalen-1-yl)-1*H*-benzo[*d*][1,2,3]triazole (3ah)<sup>[14]</sup>

Chromatography Pentane/EA = 10:1 (v/v), 38.5 mg (79%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.29 – 8.15 (m, 1H), 8.14 – 8.02 (m, 1H), 8.00 (dt, *J* = 8.3, 1.1 Hz, 1H), 7.71 – 7.64 (m, 2H), 7.63 – 7.54 (m, 1H), 7.52 – 7.39 (m, 4H), 7.34 – 7.28 (m, 1H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ 145.6, 134.7, 134.4, 132.5, 130.4, 129.1, 128.3, 128.1, 127.6, 127.0, 125.2, 124.6, 124.3, 122.6, 120.1, 110.3.



#### 1-benzyl-6-fluoro-1*H*-benzo[*d*][1,2,3]triazole (3ai)<sup>[15]</sup>

Chromatography Pentane/EA = 10:1 (v/v), 32.1 mg (71%), 2.9:1 rr.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.98 – 7.88 (m, 0.41 H), 7.64 – 7.54 (m, 0.94 H), 7.32 – 7.16 (m, 7.98 H), 7.13 – 6.97 (m, 1.51 H), 6.94 – 6.84 (m, 0.45 H), 5.75 (s, 2 H), 5.71 (s, 0.85 H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 162.0 (d, *J* = 246.8 Hz), 159.6 (d, *J* = 241.6 Hz), 146.5 (d, *J* = 12.1 Hz), 143.1, 134.3, 134.2, 129.7, 129.1, 129.0, 128.6, 127.5, 127.5, 121.5 (d, *J* = 11.0 Hz), 117.4 (d, *J* = 27.9 Hz), 113.9 (d, *J* = 27.0 Hz), 110.7 (d, *J* = 10.2 Hz), 104.5 (d, *J* = 24.3 Hz), 95.5 (d, *J* = 27.9 Hz), 52.6, 52.3.

<sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>) δ -105.29 - -113.77 (m, 1F), -117.71 - -117.97 (m; 1F).



#### 1-benzyl-6-chloro-1*H*-benzo[*d*][1,2,3]triazole (3aj)<sup>[15]</sup>

Chromatography Pentane/EA = 10:1 (v/v), 33.4 mg (69%), 1.7:1 rr.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 8.05 – 7.80 (m, 1.67H), 7.57 – 6.99 (m, 11.7H), 5.75 (s, 2H), 5.72 (s, 1.2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ 146.9, 144.8, 134.2, 134.2, 133.8, 133.3, 131.4, 129.9, 129.8, 129.1, 129.1, 128.6, 128.3, 127.5, 125.2, 124.4, 120.9, 119.4, 110.7, 109.5, 52.5, 52.3.



#### 1-benzyl-7-chloro-4-methoxy-1*H*-benzo[*d*][1,2,3]triazole (3ak)

Chromatography Pentane/EA = 10:1 (v/v), 48.2 mg (88%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.28 – 7.08 (m, 6H), 6.51 (d, *J* = 8.3 Hz, 1H), 6.03 (s, 2H), 4.00 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ150.7, 139.3, 136.1, 131.3, 128.9, 128.7, 128.1, 127.1, 106.9, 104.1, 56.4, 52.4.

HRMS (ESI-TOF): m/z calcd. for  $C_{14}H_{12}CIN_3ONa^+$  [M+Na<sup>+</sup>] 296.0561, found 296.0568.



#### 1-benzyl-7-bromo-4-methoxy-1*H*-benzo[*d*][1,2,3]triazolee (3al)

Chromatography Pentane/EA = 8:1 (v/v), 60.8 mg (96%), 19:1 *rr*.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.47 (dd, *J* = 8.3, 0.4 Hz, 1H), 7.42 – 7.13 (m, 5H), 6.57 (d, *J* = 8.3 Hz, 1H), 6.17 (s, 2H), 4.09 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ151.3, 139.1, 136.2, 132.4, 132.3, 128.6, 127.9, 126.9, 104.8, 92.4, 56.4, 52.0. HRMS (ESI-TOF): m/z calcd. for C<sub>14</sub>H<sub>12</sub>BrN<sub>3</sub>ONa<sup>+</sup> [M+Na<sup>+</sup>] 340.0056, found 340.0065.



### 1-benzyl-7-bromo-4-methoxy-1*H*-benzo[*d*][1,2,3]triazolee (3am)

Chromatography Pentane/EA = 8:1 (v/v), 34.5 mg (47%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.37 – 7.30 (m, 3H), 7.29 – 7.19 (m, 3H), 7.06 (d, *J* = 8.9 Hz, 1H), 5.81 (s, 2H), 3.94 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ156.1, 149.1, 134.3, 129.0, 128.5, 128.3, 127.5, 114.6, 110.2, 74.2, 57.9, 52.8.

HRMS (ESI-TOF): m/z calcd. for  $C_{14}H_{12}IN_3ONa^+$  [M+Na<sup>+</sup>] 387.9917, found 387.9926.



### 1-benzyl-7-fluoro-4,5-dimethoxy-1*H*-benzo[*d*][1,2,3]triazole (3an)

Chromatography Pentane/EA = 5:1 (v/v), 50.8 mg (88%), 6.3:1 rr.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.28 – 7.18 (m, 5H), 6.84 (d, *J* = 11.2 Hz, 1H), 5.77 (s, 2H), 4.34 (s, 3H), 3.80 (s, 3H).

<sup>19</sup>F NMR (282 MHz, CDCl<sub>3</sub>) δ -126.78 (d, J = 11.2 Hz, 0.16F), -136.63 (d, J = 11.1 Hz, 1F).

HRMS (ESI-TOF): m/z calcd. for  $C_{15}H_{14}FN_3O_2Na^+$  [M+Na<sup>+</sup>] 310.0962, found 310.0962.



### 1-benzyl-7-fluoro-4-methoxy-6-methyl-1*H*-benzo[*d*][1,2,3]triazole (3ao)

Chromatography Pentane/EA = 10:1 (v/v), 51.0 mg (94%), 1.6:1 rr.

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.28 – 7.11 (m, 7.8H), 6.39 (d, *J* = 4.7 Hz, 0.6H), 6.28 (d, *J* = 4.7 Hz, 0.96H), 5.84 (s, 1.21H), 5.76 (s, 1.99H), 3.93 (s, 3H), 3.79 (s, 1.85H), 2.24 (m, 4.88H).

 $^{19}F$  NMR (282 MHz, CDCl<sub>3</sub>)  $\delta$  -140.02 (s, 0.59F), -145.08 - -146.79 (m, 1F).

HRMS (ESI-TOF): m/z calcd. for C<sub>15</sub>H<sub>14</sub>FN<sub>3</sub>ONa<sup>+</sup> [M+Na<sup>+</sup>] 294.1013, found 294.1015.



### 1-benzyl-4-(benzyloxy)-7-bromo-1*H*-benzo[*d*][1,2,3]triazole (3ap)

Chromatography Pentane/EA = 8:1 (v/v), 66.4 mg (84%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.45 – 7.34 (m, 2H), 7.30 – 6.94 (m, 9H), 6.49 (d, *J* = 8.3 Hz, 1H), 6.04 (s, 2H), 5.33 (s, 2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ 150.2, 139.3, 136.1, 136.0, 132.5, 132.2, 128.6, 128.5, 128.1, 127.9, 127.4, 126.9, 106.9, 92.6, 71.3, 52.0.

HRMS (ESI-TOF): m/z calcd. for  $C_{20}H_{16}BrN_3ONa^+$  [M+Na<sup>+</sup>] 416.0369, found 416.0373.



### 1-benzyl-7-bromo-4,5-dimethoxy-1*H*-benzo[*d*][1,2,3]triazole (3aq)

Chromatography Pentane/EA = 5:1 (v/v), 39.3 mg (57%).

 $^{1}H NMR (300 MHz, CDCl_{3}) \\ \delta 7.29 - 7.17 (m, 4H), \\ 7.14 - 7.07 (m, 2H), \\ 6.04 (s, 2H), \\ 4.45 (s, 3H), \\ 3.83 (s, 3H). \\ 1.40 (s, 2H), \\ 4.45 (s, 3H), \\ 3.83 (s, 3H). \\ 3.84 (s, 3H)$ 

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ145.4, 140.6, 139.6, 136.2, 128.7, 128.6, 128.0, 127.0, 121.6, 91.6, 61.7, 58.5, 52.0. HRMS (ESI-TOF): m/z calcd. for C<sub>15</sub>H<sub>14</sub>BrN<sub>3</sub>O<sub>2</sub>Na<sup>+</sup> [M+Na<sup>+</sup>] 370.0161, found 370.0162.



3-benzyl-4-bromo-3*H*-[1,3]dioxolo[4',5':3,4]benzo[1,2-*d*][1,2,3]triazole (3ar)

Chromatography Pentane/EA = 5:1 (v/v), 43.5 mg (66%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.30 – 7.15 (m, 4H), 7.12 – 7.00 (m, 2H), 6.11 (s, 2H), 6.05 (s, 2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ144.3, 136.1, 136.1, 133.5, 129.2, 128.7, 128.0, 126.9, 115.0, 103.3, 91.5, 52.3.

HRMS (ESI-TOF): m/z calcd. for C<sub>14</sub>H<sub>10</sub>BrN<sub>3</sub>O<sub>2</sub>Na<sup>+</sup> [M+Na<sup>+</sup>] 353.9848, found 353.9852.



1-benzyl-7-chloro-6-methoxy-1*H*-benzo[*d*][1,2,3]triazole (3as)

Chromatography Pentane/EA = 8:1 (v/v), 33.4 mg (61%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.26 – 7.21 (m, 3H), 7.20 – 7.14 (m, 2H), 7.12 – 7.04 (m, 2H), 5.73 (s, 2H), 3.86 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ152.0, 145.1, 134.3, 129.3, 129.0, 128.6, 127.5, 115.9, 111.3, 108.2, 57.9, 52.6.

HRMS (ESI-TOF): m/z calcd. for  $C_{14}H_{12}ClN_3ONa^+$  [M+Na<sup>+</sup>] 296.0561, found 296.0562.



### 1-benzyl-7-bromo-6-methoxy-1*H*-benzo[*d*][1,2,3]triazole (3at)

Chromatography Pentane/EA = 8:1 (v/v), 39.6 mg (62%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>) δ 7.37 – 7.30 (m, 3H), 7.29 – 7.20 (m, 3H), 7.16 – 7.09 (m, 1H), 5.82 (s, 2H), 3.95 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ153.2, 146.4, 134.3, 129.0, 129.0, 128.5, 127.5, 115.6, 109.1, 100.1, 57.9, 52.7. HRMS (ESI-TOF): m/z calcd. for C<sub>14</sub>H<sub>12</sub>BrN<sub>3</sub>ONa<sup>+</sup> [M+Na<sup>+</sup>] 340.0056, found 340.0054.



3au, derived from Clofibrate

ethyl 2-((1-benzyl-7-chloro-1*H*-benzo[*d*][1,2,3]triazol-4-yl)oxy)-2-methylpropanoate (3au)

Chromatography Pentane/EA = 6:1 (v/v), 27.8 mg (37%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.29 – 7.09 (m, 6H), 6.43 (d, J = 8.4 Hz, 1H), 6.04 (s, 2H), 4.16 (q, J = 7.1 Hz, 2H), 1.70 (s, 6H), 1.13 (t, J = 7.1 Hz, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 173.6, 146.7, 140.6, 136.1, 131.4, 128.7, 128.4, 128.1, 127.1, 109.8, 107.7, 80.7, 61.6, 52.5, 25.3, 14.0.

HRMS (ESI-TOF): m/z calcd. for  $C_{19}H_{20}CIN_3O_3Na^+$  [M+Na<sup>+</sup>] 396.1085, found 396.1088.



3av, derived from Fenofibrate

isopropyl 2-((1-benzyl-7-(4-chlorobenzoyl)-1*H*-benzo[*d*][1,2,3]triazol-4-yl)oxy)-2-methylpropanoate (3av)

Chromatography Pentane/EA = 5:1 (v/v), 33.8 mg (34%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.39 – 7.32 (m, 2H), 7.30 – 7.16 (m, 3H), 7.00 – 6.81 (m, 3H), 6.78 – 6.65 (m, 2H), 6.37 (d, J = 8.2 Hz, 1H), 5.99 (s, 2H), 5.01 (p, J = 6.3 Hz, 1H), 1.76 (s, 6H), 1.09 (d, J = 6.3 Hz, 6H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 192.0, 172.5, 151.5, 139.2, 135.7, 135.0, 132.1, 131.4, 129.4, 128.5, 128.4, 127.7, 127.6, 116.3, 106.6, 81.1, 69.4, 53.9, 25.4, 21.5.

HRMS (ESI-TOF): m/z calcd. for  $C_{27}H_{26}CIN_3O_4Na^+$  [M+Na<sup>+</sup>] 514.1504, found 514.1507.



### 1-(3-((*tert*-butyldimethylsilyl) oxy) propyl)-7-chloro-4-methoxy-1*H*-benzo[d] [1,2,3] triazole (3aw)

Chromatography Pentane/EA = 10:1 (v/v), 58.3 mg (82%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.25 (d, J = 8.3 Hz, 1H), 6.54 (d, J = 8.3 Hz, 1H), 5.04 – 4.94 (m, 2H), 4.03 (s, 3H), 3.67 (t, J = 5.9 Hz, 2H), 2.24 – 2.06 (m, 2H), 0.84 (s, 9H), 0.00 (s, 6H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ150.7, 139.2, 131.3, 128.5, 106.9, 103.8, 59.8, 56.4, 46.8, 34.2, 25.8, 18.2, -5.5.

HRMS (ESI-TOF): m/z calcd. for  $C_{16}H_{26}ClN_3O_2SiNa^+$  [M+Na<sup>+</sup>] 378.1375, found 378.1376.



### 1-benzyl-1*H*-benzo[*d*][1,2,3]triazole-4,5,6,7-d4 (3ax)

Chromatography Pentane/EA = 10:1 (v/v), 32.7 mg (77%).

 $^{1}$ H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.33 – 7.13 (m, 5H), 5.75 (s, 2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 146.2, 134.7, 132.7, 128.9, 128.4, 127.5, 127.2, 123.7 – 123.1 (m), 119.8, 109.6, 52.2.

HRMS (ESI-TOF): m/z calcd. for  $C_{13}H_7D_4N_3H^+$  [M+H<sup>+</sup>] 214.1282, found 214.1287.

5. Transformation of products.

5.1 Gram reaction.



To a 200 mL of Schlenk tube were added aryl sulfonium salt **1al** (6 mmol, 1.2 equiv.), NaOtBu (10 mmol, 2.0 equiv.). ). PhCF<sub>3</sub> (50 mL) and azide **2a** (5 mmol, 1.0 equiv) were added via syringe. The reaction mixture was stirred at 80 °C for 6 h. After reaction, cooling to room temperature. The crude product was purified by silicagel chromatography (pentane/EA) to afford the corresponding product **3al** (1.54 g, 97%).

5.2 Prcedure for the synthesis of 4t.



A 5 mL snap vial equipped with a magnetic stir bar was charged with CuI (20 mol%), 3t(1.0 equiv) and evacuated under high vacuum and backfilled with N<sub>2</sub>. THF (0.2 M) and Phenylacetylene (2.0 equiv) were added via syringe. The reaction mixture was stirred (500 rpm) at 60 °C for 4 h. After reaction, cooling to room temperature. The crude product was purified by silica gel chromatography (pentane/EA) to afford the corresponding product 4t.



#### 1-(5-(4-phenyl-1*H*-1,2,3-triazol-1-yl)pentyl)-1*H*-benzo[*d*][1,2,3]triazole (4t)<sup>[16]</sup>

Chromatography Pentane/EA = 2:1 (v/v), 25.4 mg (76%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.03 (dt, *J* = 8.3, 1.0 Hz, 1H), 7.91 – 7.77 (m, 2H), 7.69 (s, 1H), 7.53 – 7.23 (m, 6H), 4.61 (t, *J* = 7.0 Hz, 2H), 4.34 (t, *J* = 7.0 Hz, 2H), 2.13 – 1.89 (m, 4H), 1.57 – 1.31 (m, 2H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ 147.7, 145.9, 132.8, 130.4, 128.8, 128.1, 127.3, 125.6, 123.9, 120.0, 119.5, 109.1, 49.9, 47.6, 29.5, 28.8, 23.5.

HRMS (ESI-TOF): m/z calcd. for  $C_{19}H_{20}N_6Na^+$  [M+Na<sup>+</sup>] 355.1642, found 355.1650.

5.3 Procedure for the synthesis of 5al.



A 5 mL snap via lequipped with a magnetic stir bar was charged with  $Pd(PPh_3)_2Cl_2(3 mol\%)$ , CuI (2 mol%), **3al** (0.2 mmol, 1.0 equiv) and evacuated under high vacuum and backfilled with N<sub>2</sub>. Et<sub>3</sub>N (2 ml) and Phenylacetylene (1.1 equiv) were added via syringe. The reaction mixture was stirred (500 rpm) at 60 °C for 12 h. After reaction, cooling to room temperature. The crude product was purified by silica gel chromatography (pentane/EA) to afford the corresponding product **5al**.



### 1-benzyl-4-methoxy-7-(phenylethynyl)-1*H*-benzo[*d*][1,2,3]triazole (5al)<sup>[17]</sup>

Chromatography Pentane/EA = 6:1 (v/v), 44.7 mg (66%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.47 (d, J = 8.1 Hz, 1H), 7.38 – 7.29 (m, 2H), 7.28 – 6.98 (m, 8H), 6.58 (d, J = 8.1 Hz, 1H), 6.14 (s, 2H), 4.03 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ 152.3, 138.1, 136.1, 133.9, 133.6, 131.2, 128.7, 128.6, 128.5, 128.0, 127.3, 122.6, 103.9, 98.2, 93.5, 84.6, 56.4, 51.7.

HRMS (ESI-TOF): m/z calcd. for  $C_{22}H_{17}N_3ONa^+$  [M+Na<sup>+</sup>] 362.1264, found 362.1260.

5.4 Prcedure for the synthesis of 6al.



A 4 mL snap vial equipped with a magnetic stir bar was charged with  $Pd(OAc)_2 (1.5 \text{ mol}\%)$ ,  $nBuPAd_2 (4.5 \text{mmol}\%)$ , **3al** (0.2 mmol, 1 equiv) and closed with a rubber-based septum. The vial was evacuated and backfilled with argon. nBuOH (1 mL) and TMEDA (0.75 equiv) were added via syringe. The vial was then connected to a tmosphere with a cannula and transferred into a 300 mL autoclave, under argon counterflow. The closed autoclave was flushed three times with nitrogen (~ 5 bar), three times with CO (~ 5 bar), and 6 bar of carbon monoxide (measured by pressure meter) was charged. The autoclave was then placed into an aluminum block on a magnetic stirrer. The reaction mixture was stirred (500 rpm) at 120 °C for 12 h. After reaction, cooling to room temperature. The crude product was purified by silica gel chromatography (pentane/EA) to afford the corresponding product **6a**l.



### butyl 1-benzyl-4-methoxy-1*H*-benzo[*d*][1,2,3]triazole-7-carboxylate (6al)<sup>[18]</sup>

Chromatography Pentane/EA = 5:1 (v/v), 59.9 mg (88%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  8.01 (d, J = 8.3 Hz, 1H), 7.32 – 7.13 (m, 3H), 7.11 – 6.94 (m, 2H), 6.67 (d, J = 8.4 Hz, 1H), 6.39 (s, 2H), 4.26 (t, J = 6.6 Hz, 2H), 4.14 (s, 3H), 1.75 – 1.59 (m, 2H), 1.41 – 1.35 (m, 2H), 0.95 (t, J = 7.4 Hz, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 164.6, 155.4, 139.2, 136.5, 133.3, 132.8, 128.3, 127.5, 127.0, 108.7, 102.7, 64.9, 56.5, 54.2, 30.6, 19.1, 13.6.

HRMS (ESI-TOF): m/z calcd. for  $C_{19}H_{21}N_3O_3Na^+$  [M+Na<sup>+</sup>] 362.1475, found 362.1475.

5.5 Prcedure for the synthesis of 7al.



A 5 mL snap vial equipped with a magnetic stir bar was charged with  $Pd(PPh_3)_2Cl_2$  (5 mol%),  $PhB(OH)_2$  (1.2 equiv),  $K_3PO_4$  (2.5 equiv), **3al** (0.2 mmol, 1.0 equiv) and evacuated under high vacuum and backfilled with N<sub>2</sub>. dioxane (1 ml) and H<sub>2</sub>O (0.1 ml) were added via syringe. The reaction mixture was stirred (500 rpm) at 100 °C for 16 h. After reaction, cooling to room temperature. The crude product was purified by silica gel chromatography (pentane/EA) to afford the corresponding product **7al**.



1-benzyl-4-methoxy-7-phenyl-1*H*-benzo[*d*][1,2,3]triazole (7al)<sup>[19]</sup>

Chromatography Pentane/EA = 6:1 (v/v), 64.4 mg (quant.).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.38 – 7.13 (m, 3H), 7.10 – 6.88 (m, 6H), 6.60 (d, J = 7.9 Hz, 1H), 6.41 – 6.30 (m, 2H), 5.48 (s, 2H), 4.02 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>)δ 150.9, 138.6, 137.2, 135.4, 132.1, 129.8, 129.7, 128.1, 128.1, 127.7, 127.4, 126.5, 118.7, 103.1, 56.1, 52.7.

HRMS (ESI-TOF): m/z calcd. for  $C_{20}H_{17}N_3ONa^+$  [M+Na<sup>+</sup>] 338.1264, found 338.1270.

5.6 Procedure for the synthesis of 8al.



A 5 mL snap vial equipped with a magnetic stir bar was charged with  $Pd(OAc)_2$  (3 mol%), K<sub>3</sub>PO<sub>4</sub> (1.4 equiv), **3al** (0.2 mmol, 1.0 equiv) and evacuated under high vacuum and backfilled with N<sub>2</sub>. DMAc (0.5 ml) and styrene (1.2 equiv) were added via syringe. The reaction mixture was stirred (500 rpm) at 140 °C for 12 h. After reaction, cooling to room temperature. The crude product was purified by silica gel chromatography (pentane/EA) to afford the corresponding product **8al**.



### (E)-1-benzyl-4-methoxy-7-(4-methylstyryl)-1H-benzo[d][1,2,3]triazole (8al)<sup>[20]</sup>

Chromatography Pentane/EA = 6:1 (v/v), 59.5 mg (84%).

<sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>)  $\delta$  7.45 (dt, J = 8.1, 0.7 Hz, 1H), 7.37 – 7.28 (m, 3H), 7.20 – 7.06 (m, 7H), 6.82 (d, J = 15.9 Hz, 1H), 6.69 (d, J = 8.1 Hz, 1H), 6.02 (s, 2H), 4.12 (s, 3H), 2.37 (s, 3H).

<sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>) δ 151.1, 138.6, 137.7, 136.3, 134.1, 132.7, 130.9, 129.4, 129.0, 128.1, 126.3, 126.2, 125.9, 121.6, 115.5, 103.9, 56.2, 53.2, 21.2.

### 6. Reference

- [1] V. Tona, A. de la Torre, M. Padmanaban, S. Ruider, L. Gonzalez, N. Maulide, *J. Am. Chem. Soc.* 2016, **138**, 8348-8351.
- [2] R. A. Roberts, B. E. Metze, A: Nilova, D. Stuart, J. Am. Chem. Soc. 2023, 145, 3306-3311.
- [3] Z. Zhong, R. Hong, X. Wang, *Tetrahedron Lett.*, 2010, **51**, 6763-6766.
- [4] X. Liu, G. Q. Yu, J. H. Li, D. Wang, Y. X. Chen, K. Q. Shi, B. H. Chen, Synlett 2013, 24, 1588-1594.
- [5] A. Tanimoto, T. Yamamoto, Adv. Synth. Catal. 2004, 346, 1818-1823.
- [6] Z. Rezaei, S. Khabnadideh, K. Pakshir, Z. Hossaini, F. Amiri, E. Assadpour, Eur. J. Med. Chem. 2009, 44, 3064-3067.
- [7] A. Diaz-Ortiz, A. de la Hoz, J. Alcazar, J. R. Carrillo, M. A. Herrero, A. Fontana, J. de M. Munoz, P. Prieto, A. de Cozar. Combinatorial Chemistry & High Throughput Screening, 2011, **14**, 109-116.
- [8] J. J. Gair, R. L. Grey, S. Giroux, M. A. Brodney, Org. Lett. 2019, 21, 2482-2487.
- [9] F. Shi, J. P. Waldo, Y. Chen, R. C. Larock, Org. Lett. 2008, 10, 2409-2412.
- [10] V. Zimmermann and S. Bräse, J. Comb. Chem. 2007, 9, 1114.
- [11] Q.-L. Liu, D.-D. Wen, C.-C. Hang, Q.-L. Li, Y.-M. Zhu, Helvetica Chimica Acta, 2010, 93, 1350-1354.
- [12] H. Huang, Z. M. Strater, M. Rauch, J. Shee, T. J. Sisto, C. Nuckolls, T. H. Lambert, *Angew. Int. Ed. Chem.* 2019, **58**, 13318-13322.
- [13] F. Zhang, J. E. Moses, Org. Lett. 2009, 11, 1587-1590.
- [14] H. Yi, Z. Tang, C. Bian, H. Chen, X. Qi, X. Yue, Y. Lan, J.-F. Lee, A. Lei, *Chem. Commun.* 2017, **53**, 8984-8987.
- [15] Q. Chen, H. Yu, Z. Xu, L. Lin, X. Jiang, R. Wang, J. Org. Chem. 2015, 80, 6890-6896.
- [16] H. C. Kolb, M. G. Finn, K. B. Sharpless, Angew. Chem. 2001, 113, 2056-2075.
- [17] A. S. Narode. Y.-S. Ho, M.-J. Cheng, R.-S. Liu, Org. Lett. 2023, 25, 1589-1594.
- [18] H. Neumann, A. Brennfuhrer, P. Groß, T. Riermeier, J. Almena, M. Beller, Adv. Synth. Catal. 2006, 348, 1255-1261.
- [19] G. L. Bartholomew, F. Carpaneto, R. Sarpong, J. Am. Chem. Soc. 2022, 144, 22309-22315.
- [20] W. Yang, C. T. To, K. S. Chan, Org. Biomol. Chem. 2019, 17, 6757-6761.

# 7. NMR spectra of products































































































































S90









